Acquisition Opportunity Diablo Clinical Research was acquired by Flourishresearch on February 19, 2025, signaling potential collaboration, integration opportunities, or joint go-to-market efforts with a larger multi-site organization in cardiovascular, metabolic, neuroscience, and infectious disease spaces.

Cardinal Patient Base With a database of over 12,000 patients and a track record of more than 600 studies across multiple therapeutic areas, there is a substantial pipeline for new trials, patient recruitment partnerships, and ongoing engagement programs for sponsor studies.

Therapeutic Depth Staff includes six MDs across endocrinology, internal medicine, cardiology, and neurology, enabling expanded collaboration on Phase I–IV trials and medical device studies that align with sponsor trial needs in these disciplines.

Regional Footprint Longstanding Walnut Creek presence and San Francisco Bay Area access provide geographic advantages for regional trials, real-world site feasibility assessments, and faster enrollment for sponsors seeking West Coast participation.

Tech & Analytics Existing tech stack (MySQL, Google Analytics, Office 365, HTTP/3) supports data management and digital outreach; opportunities exist to offer enhanced data capabilities, patient engagement tooling, and sponsor reporting enhancements to improve trial efficiency.